BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease | MicrobiomeTrials← Back to trialsNCT07729995
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-10Est. Completion: 2030-03
Enrollment target: 94 participants Locations- Boston Children's Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Rheumatoid Arthritis (RA)
This is a Phase 1, open-label, first-in-human study to investigate the safety, tolerability, pharmacokinetics and pharma…
Bayswater, AustraliaEst. completion Dec 2027
Rheumatoid ArthritisSystemic Lupus Erythematosus
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD fol…
Birmingham, United StatesEst. completion Jun 27, 2028
Phase 1
Recruiting
Systemic SclerosisIdiopathic Inflammatory MyopathiesRheumatoid Arthritis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell th…
Tucson, United StatesEst. completion Feb 22, 2028